Catalyst Therapeutics' controversial, $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...
Tenpoint Therapeutics’ presbyopia drug showed “significant improvements” in near vision and reading speed in a Phase 3 trial. The biotech said the results keep it on track for an FDA filing in the ...